No results for ‘’
Strides Pharma Science Ltd
₹1223.10
(0.97%)
Fri, 25 Sept 2026, 11:29 pm
Health Technology
Pharmaceuticals: Major
24.5KStrides Pharma Science Debt to Equity Ratio
| Particulars | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 25.49 | 39.26 | 0 | 3.62 | 12.16 | 18.28 | 10.46 | 8.31 | 0 | 4530 | 92.09 | 54.19 | 0 | 80.77 | 119.66 | 29.77 | 0 | 0 | 0 | 15.19 |
| Price to book ratio | 4.15 | 3.89 | 4.35 | 0.98 | 1.23 | 2.02 | 1.71 | 3.18 | 2.29 | 6.14 | 3.66 | 3.57 | 2.44 | 1.59 | 1.14 | 2.73 | 1.32 | 1.17 | 3.38 | 2.42 |
| Price to sales ratio | 2.33 | 2.01 | 1.36 | 0.46 | 1.01 | 1.32 | 0.93 | 3.12 | 2.29 | 5.89 | 3.16 | 3.56 | 2.11 | 1.99 | 1.08 | 2.31 | 1.02 | 0.70 | 1.86 | 1.38 |
| Price to cash flow ratio | 27.07 | 22.19 | 23.86 | 7.24 | 0 | 10.86 | 5.02 | 0 | 0 | 117.50 | 0 | 76.66 | 0 | 0 | 50.55 | 21.71 | 0 | 0 | 16.81 | 13.47 |
| Enterprise value | 1638Cr | 2107Cr | 2140Cr | 1944Cr | 2990Cr | 3484Cr | 4702Cr | 8375Cr | 2289Cr | 7252Cr | 11505Cr | 13095Cr | 8076Cr | 6798Cr | 4835Cr | 9682Cr | 5972Cr | 5201Cr | 9298Cr | 7864Cr |
| Enterprise value to EBITDA ratio | 15.34 | 18.15 | 0 | 9.87 | 16 | 14.90 | 11.06 | 15.42 | 16.98 | 30.14 | 27.47 | 24.72 | 19.89 | 34.28 | 13.51 | 18.74 | 0 | 14.20 | 18.06 | 11.08 |
| Debt to equity ratio | 1.41 | 1.46 | 4.62 | 3.13 | 1.75 | 1.57 | 1.87 | 0.79 | 0.54 | 0.78 | 1.33 | 1.35 | 1.02 | 1.22 | 0.88 | 0.85 | 1.28 | 1.37 | 1.18 | 0.74 |
| Return on equity % | 18.75 | 11.69 | -15.58 | 31.20 | 17.60 | 11.59 | 16.91 | 49.81 | -12.28 | 0.15 | 6.93 | 8.64 | 2.09 | 3.29 | 1.90 | 9.60 | -17.92 | -9.68 | -5.54 | 17.33 |
Strides Pharma Science Ltd Debt to Equity Ratio
The Strides Pharma Science Ltd Debt to Equity Ratio is a key financial metric used by investors to evaluate Strides Pharma Science Ltd's valuation, profitability, and overall financial performance. Tracking the Strides Pharma Science Ltd Debt to Equity Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Strides Pharma Science Ltd (NSE: STAR, BSE: 532531) is currently trading at ₹1223.10, with a market capitalization of ₹11245.07Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Strides Pharma Science Ltd Debt to Equity Ratio is essential for fundamental analysis.
Strides Pharma Science Ltd Debt to Equity Ratio Current Value
The current Strides Pharma Science Ltd Debt to Equity Ratio stands at 0.74.
The Strides Pharma Science Ltd Debt to Equity Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Strides Pharma Science Ltd Debt to Equity Ratio Historical Trend
The Strides Pharma Science Ltd Debt to Equity Ratio has shown the following historical trend:
- 2024: 0.74
- 2023: 1.18
- 2022: 1.37
- 2021: 1.28
- 2020: 0.85
The decline in Strides Pharma Science Ltd Debt to Equity Ratio indicates improving financial efficiency or better earnings growth.
What Strides Pharma Science Ltd Debt to Equity Ratio Indicates for Investors
The Strides Pharma Science Ltd Debt to Equity Ratio plays a crucial role in understanding the company's financial health and valuation.
The D/E ratio measures financial leverage and balance sheet strength.
Strides Pharma Science Ltd Debt to Equity Ratio Analysis Summary
The Strides Pharma Science Ltd Debt to Equity Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Strides Pharma Science Ltd Debt to Equity Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Strides Pharma Science Ltd Debt to Equity Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.